Misplaced Pages

Galderma

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Galderma Laboratories) Swiss pharmaceutical company
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Misplaced Pages's content policies, particularly neutral point of view. Please discuss further on the talk page. (April 2024) (Learn how and when to remove this message)
This article may need to be rewritten to comply with Misplaced Pages's quality standards. You can help. The talk page may contain suggestions. (January 2025)
This article may require copy editing for grammar, style, cohesion, tone, or spelling. You can assist by editing it. (January 2025) (Learn how and when to remove this message)
(Learn how and when to remove this message)

Galderma S.A.
Company typePublic
Traded asSIXGALD
Industry
Founded1981; 44 years ago (1981)
HeadquartersZug, Switzerland
Key people
RevenueIncrease US$4.08 billion (2023)
Owner
Number of employees6,500 (2024)
Websitegalderma.com

Galderma SA is a Swiss pharmaceutical company specializing in dermatological treatments and skin care products. Formerly a subsidiary of L'Oréal and Nestlé, it had been held by a consortium of private institutional investors since 2019, until IPO in 2024.

Galderma was formed in 1981 as a joint venture between Nestlé and L'Oréal, then it became a subsidiary of Nestlé. Since 2019, it belongs to an investment fund. The company, headed by president and CEO Flemming Ørnskov (ex-Shire), has 33 sites in 100 countries with a worldwide network of distributors and employs more than 4,600 people. The headquarters is based in Zug, Switzerland.

History

The origins of Galderma date back to 1961 and the founding of the Owen dermatology company in Dallas, Texas, USA by M. Owen.

In 1979, Hans Schaefer founded the International Center for Dermatological Research (CIRD) in Sophia Antipolis, with the support of the CEO of L'Oréal, François Dalle, who wanted to diversify his cosmetic research into the drug sector. At the same time, Nestlé, which also had ambitions in dermatology bought the Owen laboratory.

L'Oréal and Nestlé joined forces to create Galderma in 1981 (CIRD became Galderma R&D). It was a joint venture between the two companies.

Galderma expanded by specializing in the research, development and commercialization of products for dermatology (skin care) patients. It reached a significant size, with 38 subsidiaries present in 100 countries in the 2010s. It diversified into aesthetic medicine products with the botulinum toxin Azzalure, a field in which it strengthened in 2010 with the acquisition of the Swedish medical-device company Q-Med.

In 2014, Nestlé bought back all the shares from L'Oréal, thus creating a new unit of Nestlé group called Nestle Skin Health. The transaction had a value of €3.1 billion (US$4.23 billion) and was paid for by Nestlé with 21.2 million L'Oréal shares.

In 2019, Nestlé sold Galderma for $10.2 billion to a consortium comprising the EQT VIII fund, Luxinva (a wholly owned subsidiary of Abu Dhabi Investment Authority), PSP Investments and other institutional investors. Since then, it has been the largest independent dermatology company in the world.

In November 2021, Galderma bought California-based Alastin, a firm specialising in specialist skincare products, for an undisclosed price.

In June 2022, Galderma announced positive results in two Phase III trials for liquid botulinum toxin A, showing RelabotulinumtoxinA was well tolerated. This result primes the company to apply for approval in the US and other global markets.

Also in June 2022, Galderma announced positive data from Phase III trial, showing efficacy and safety of nemolizumab in patients with prurigo nodularis. Nemolizumab is a monoclonal antibody that blocks the signaling of IL-31, a neuroimmune cytokine involved in the pathogenesis of prurigo nodularis.

On 6 March 2023, Galderma announced its intention to list on the Swiss stock exchange.

The IPO took place on 22 March 2024, and was one of the biggest in Europe in two years, and the largest in Switzerland since 2017. The stock price went up to 62,68 Swiss francs, up from the IPO price at 53 francs per share. Bloomberg reports that including debt, Galderma's total market value should come out in the range of $18.69 billion to $19.72 billion. The company plans to repay debt with offering proceeds.

Activities

Galderma provides a range of over-the-counter and prescription dermatological products for skin care, aesthetics and treatment of conditions including acne, rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and skin aging. Galderma's activities are divided into three business units: aesthetics, consumer care and prescription medicine. Galderma's products are sold in more than 100 countries.

Botulinum toxin

In 2007, Galderma and Ipsen signed a licensing agreement for the distribution of the botulinum toxin Dysport, known as Azzalure in the European Union. More than 40 million treatments have been performed in the United States and the European Union.

The main brands are Restylane, Azzalure, Dysport, Alluzience, Sculptra and Relfydess (relabotulinumtoxinA), which received a positive decision for use in Australia and in the European Union in July 2024.

Consumer care

Galderma's products are available over-the-counter to consumers.

The main consumer care brands are Cetaphil, with its range of skin care products for all ages; Benzac and Differin OTC for mild-to-moderate acne; and Loceryl, used to treat fungal nail infections, and Alastin.

Prescription Medicine

Disease areas are atopic dermatitis, dermato-oncology and psoriasis.

The main brands are Aklief, Benzac, Cetaphil, Epiduo, Epiduo Forte, Twyneo, Epsolay, Loceryl, Differin, Soolantra, Mirvaso, Oracea, Metvix and Nemluvio which received US Food and drug Administration approval for adult patients living with prurigo nodularis in August 2024 and for patients with atopic dermatitis in December 2024.

Research and development

The company invests substantially in research and development and sources new treatments from its own activities and from its partnerships with others. It divides its research and development departments between six sites:

Production

Galderma has manufacturing facilities at the following locations:

  • The Alby-sur-Chéran plant in France, inaugurated in 1994, supplies over 70 countries.
  • The Baie d'Urfé (Montreal) facility in Canada started production in 2000 and supplies Cetaphil globally.
  • The plant in Uppsala, Sweden, manufactures aesthetic and corrective products.
  • The Hortolândia site in the state of São Paulo, Brazil serves South America.

Governance

  • Flemming Ørnskov, chief executive officer
  • Thomas Dittrich chief financial officer
  • Adrian Murphy, vice president, head of global operations
  • Allison Pinkham, chief human resources officer

Notes and references

  1. ^ Weil, Jennifer (22 March 2024). "Galderma's Shares Soar on Stock Market Debut". Women's Wear Daily. ISSN 0043-7581.
  2. Nestlé
  3. ^ "Manufacturing". Galderma. Retrieved 1 April 2021.
  4. ^ Preston, Quincy (10 December 2021). "Global Dermatology Innovator Galderma Moving U.S. Headquarters to Downtown Dallas » Dallas Innovates". Dallas Innovates. Retrieved 16 February 2022.
  5. Heilprin, John (11 February 2014). "Nestlé exchanges stake in L'Oreal for Galderma". AP NEWS. Retrieved 1 April 2021.
  6. "UPDATE 2-Galderma bids $967 mln for Swedish implant firm Q-Med". Reuters. 13 December 2010. Retrieved 1 April 2021.
  7. Socha, Miles (11 February 2014). "L'Oréal to Buy 8% of Share Capital From Nestlé". WWD. Retrieved 11 February 2014.
  8. "Ex-Shire CEO Flemming Ornskov emerges as Galderma CEO after $10B Nestlé spinout". FiercePharma. 8 October 2019. Retrieved 1 April 2021.
  9. Schuetze, Silke Koltrowitz, Arno (16 May 2019). "Nestle makeover advances with $10 billion sale of skin health unit". Reuters. Retrieved 1 April 2021.{{cite news}}: CS1 maint: multiple names: authors list (link)
  10. "Galderma to become the world's largest independent global dermatology company after completion of CHF 10.2 billion carve-out of Nestlé Skin Health". Galderma. Retrieved 1 April 2021.
  11. Farr, Emma-victoria (29 November 2021). "Galderma buys U.S. skincare firm Alastin ahead of potential Zurich IPO". Reuters. Retrieved 29 November 2021.
  12. "Galderma announces positive results in two Phase III trials for liquid botulinum toxin A". Aesthetic Medicine. June 2022. Retrieved 16 January 2023.
  13. "An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis". ClinicalTrials.Gov, U.S. National Library of Medicine. June 2022. Retrieved 16 January 2023.
  14. "Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis". Yahoo! Finance. 22 June 2022. Retrieved 16 January 2023.
  15. "Skin care company Galderma seeks $2.3 bln in Swiss IPO". Reuters. 6 March 2024. Retrieved 7 March 2024.
  16. Swetha Gopinath and Allegra Catelli (22 March 2024). "Galderma Surges in Debut, Bolstering Europe IPO Recovery". www.bloomberg.com. Retrieved 14 June 2024.
  17. "Galderma Stock Surges in Debut on Swiss Stock Exchange". beautymatter.com. Retrieved 14 June 2024.
  18. ^ Dave Graham and John Revill (22 March 2024). "Skin care company Galderma's shares soar on market debut". Reuters.com. Retrieved 14 June 2024.
  19. Becker, Zoey (22 March 2024). "Skincare products maker Galderma gears up for long-awaited $2.6B IPO". Fierce Pharma. Retrieved 14 June 2024.
  20. "Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)". www.businesswire.com. 17 November 2020. Retrieved 1 April 2021.
  21. "Relfydess (relabotulinumtoxinA, purified Botulinum toxin type A)". Australian Government - Department of Health and Aged Care. 30 July 2024. Retrieved 2 January 2025.
  22. "Insights Into Positive Decision for Galderma's RelabotulinumtoxinA in Europe". Dermatology Times. 12 August 2024. Retrieved 2 January 2025.
  23. Dunleavy, Kevin (13 August 2024). "FDA approves Galderma's prurigo nodularis treatment Nemluvio". www.fiercepharma.com. Retrieved 2 January 2025.
  24. "FDA approves nemolizumab to treat atopic dermatitis in patients 12 years and up". Contemporary Pediatrics. 16 December 2024. Retrieved 2 January 2025.

See also

Nestlé
Divisions
Divested
[REDACTED]
Subsidiaries
Joint ventures
Dissolved
Other assets
Brands
Appliances
Baby nutrition
Baking
Bottled water
Cereals
Chocolate
and desserts
Coffee and
beverages
Dairy products
Ice cream
Prepared and
packaged food
and snacks
Purina PetCare
Uncle Tobys
Former brands and
subsidiaries
People
Related
Related articles
  • Brand owned by General Mills; Produced by General Mills in the U.S. and Canada. Produced by Cereal Partners under the Nestlé brand elsewhere. Brand owned by General Mills; U.S. and Canadian production rights controlled by Nestlé under license. U.S. production rights owned by The Hershey Company. U.S. rights and production owned by the Smarties Candy Company with a different product. U.S. rights and specific trade dress owned by Nestlé; rights elsewhere owned by Associated British Foods. Produced by Cereal Partners, branded as Nestlé. Brand owned by Post Foods; Produced by Cereal Partners and branded as Nestlé in the U.K. and Ireland. Philippine production rights owned by Alaska Milk Corporation. Singaporean, Malaysian and Thai production rights owned by Fraser and Neave. Used only in Indonesia, Thailand, and Cambodia. Used only in the Philippines. U.S. production rights owned by the Ferrara Candy Company. NA rights and specific trade dress to all packaged coffee and other products under the Starbucks brand owned by Nestlé since 2019. Brand owned by Mars, sold by Nestlé in Canada. Produced by Froneri in the U.S. since 2020.

L'Oréal
Cosmetics
Professional products
Consumer products
Luxury products
Active Cosmetics
Former
Switzerland Pharmaceutical companies of Switzerland
Portals: Categories:
Galderma Add topic